ATR: The Target of The Year – How Has this Target Progressed in 2022 & What Are the Current Challenges Faced Clinically

Time: 9:30 am
day: Day One


  • EMD Serono unveiled its new oral ATR inhibitor (M1774) with best-in-class potential
  • The search for BM-defined populations sufficient to support monotherapy registration continues
  • While there have been setbacks for chemotherapy-ATRi combinations, combinations with ICI look increasingly promising